SFCM
PTGX icon

Seven Fleet Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Seven Fleet Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$422K Sell
4,000
-4,000
-50% -$354K 0.13% 84
2025
Q4 		$699K Buy
+8,000
New +$655K 0.47% 39

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Seven Fleet Capital Management's PTGX Position: Q1 2026 in Review

Seven Fleet Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 50% in Q1 2026, selling an estimated $354K and leaving 4,000 shares worth $422K. The position accounts for 0.13% of the portfolio, ranked #84.

Seven Fleet Capital Management first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. The position peaked at $699K in Q4 2025. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Seven Fleet Capital Management held 4,000 shares of Protagonist Therapeutics worth $422K as of Q1 2026.
  • Seven Fleet Capital Management sold 4,000 Protagonist Therapeutics shares in Q1 2026, an estimated $354K.
  • Protagonist Therapeutics made up 0.13% of Seven Fleet Capital Management's portfolio in Q1 2026, its #84 holding.
  • Seven Fleet Capital Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Seven Fleet Capital Management's Protagonist Therapeutics position peaked at $699K in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.